Tumor vascular permeabilization by vascular-targeting photosensitization: effects, mechanism, and therapeutic

Bin Chen1, Brian W Pogue, Jorge M Luna

  • 1Department of Surgery, Dartmouth Medical School, Lebanon, New Hampshire, USA.

Abstract

Insights

Vascular-targeting photodynamic therapy disrupts endothelial cell barriers, increasing vascular permeability and potentially leading to tumor vascular shutdown. This mechanism involves microtubule depolymerization and has implications for drug delivery and metastasis.

Area of Science:

  • Oncology
  • Biomedical Engineering
  • Vascular Biology

Background:

  • Vascular barrier dysfunction is a known outcome of vascular-targeting photodynamic therapy (VT-PDT).
  • The precise mechanisms and therapeutic consequences of this barrier loss remain incompletely understood.

Purpose of the Study:

  • To investigate the impact of VT-PDT on vascular barrier function.
  • To elucidate the cellular mechanisms underlying VT-PDT-induced vascular permeability.
  • To explore the implications of these changes for tumor vascular function and drug delivery.

Main Methods:

  • VT-PDT was applied to MatLyLu prostate tumor models (subcutaneous and orthotopic) and endothelial cells in vitro using verteporfin.
  • Vascular permeability was assessed using Evans blue-albumin and high molecular weight dextran.
  • Intravital microscopy monitored tumor vascular changes, while immunofluorescence studied endothelial cell morphology and cytoskeleton.

Main Results:

  • VT-PDT induced significant vascular barrier dysfunction in tumors, increasing macromolecule uptake.
  • Endothelial cell retraction and intercellular gap formation were observed, linked to microtubule depolymerization and actin stress fiber formation.
  • Blood cell adhesion, thrombus formation, and subsequent vascular shutdown were noted, alongside viable tumor cells at the periphery.

Conclusions:

  • VT-PDT causes vascular permeabilization via endothelial intercellular gap formation, driven by photosensitization-induced microtubule depolymerization.
  • The loss of endothelial barrier function can result in tumor vascular shutdown.
  • These findings highlight significant implications for drug transport and tumor cell metastasis in VT-PDT treatments.

Related Concept Videos

Tumor Immunotherapy01:27

Tumor Immunotherapy

Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
Cancer Therapies02:49

Cancer Therapies

Cancer therapies are various modes of treatment, such as surgery, radiation therapy, and chemotherapy that are administered to cancer patients.
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...
Mechanism of Angiogenesis01:10

Mechanism of Angiogenesis

Blood vessel formation starts early during embryonic development, around day 7. In the extraembryonic yolk sac, mesodermal precursor cells called hemangioblast proliferate and differentiate into angioblast. Angioblasts express vascular endothelial growth factor receptor 2 or VEGFR2, which binds VEGF-A, a proangiogenic factor, guiding blood vessel formation. VEGF signaling promotes angioblasts to form a blood island in the developing embryo. Angioblasts further differentiate, giving rise to...
The Tumor Microenvironment02:17

The Tumor Microenvironment

Every normal cell or tissue is embedded in a complex local environment called stroma, consisting of different cell types, a basal membrane, and blood vessels. As normal cells mutate and develop into cancer cells, their local environment also changes to allow cancer progression. The tumor microenvironment (TME) consists of a complex cellular matrix of stromal cells and the developing tumor. The cross-talk between cancer cells and surrounding stromal cells is critical to disrupt normal tissue...